276 related articles for article (PubMed ID: 15170903)
1. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
Smolen JS; Emery P; Kalden JR; Van Riel PL; Dougados M; Strand CV; Breedveld FC
J Rheumatol Suppl; 2004 Jun; 71():13-20. PubMed ID: 15170903
[TBL] [Abstract][Full Text] [Related]
2. Leflunomide: a manageable safety profile.
van Riel PL; Smolen JS; Emery P; Kalden JR; Dougados M; Strand CV; Breedveld FC
J Rheumatol Suppl; 2004 Jun; 71():21-4. PubMed ID: 15170904
[TBL] [Abstract][Full Text] [Related]
3. Lefunomide in combination therapy.
Kalden JR; Smolen JS; Emery P; van Riel PL; Dougados M; Strand CV; Breedveld FC
J Rheumatol Suppl; 2004 Jun; 71():25-30. PubMed ID: 15170905
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
Maddison P; Kiely P; Kirkham B; Lawson T; Moots R; Proudfoot D; Reece R; Scott D; Sword R; Taggart A; Thwaites C; Williams E
Rheumatology (Oxford); 2005 Mar; 44(3):280-6. PubMed ID: 15657072
[TBL] [Abstract][Full Text] [Related]
6. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Flendrie M; Creemers MC; Welsing PM; van Riel PL
Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
[TBL] [Abstract][Full Text] [Related]
7. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
Poór G; Strand V;
Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
[TBL] [Abstract][Full Text] [Related]
10. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Dougados M; Emery P; Lemmel EM; Zerbini CA; Brin S; van Riel P
Ann Rheum Dis; 2005 Jan; 64(1):44-51. PubMed ID: 15271770
[TBL] [Abstract][Full Text] [Related]
11. The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.
Saruhan-Direskeneli G; Inanc M; Fresko I; Akkoc N; Dalkilic E; Erken E; Karaaslan Y; Kinikli G; Oksel F; Pay S; Yucel E; Yentür SP; Duymaz-Tozkir J; Yilmaz V; Inanc N; Yazici H; Konice M; Direskeneli H
Rheumatology (Oxford); 2007 Dec; 46(12):1842-4. PubMed ID: 18032542
[TBL] [Abstract][Full Text] [Related]
12. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Verschueren P; Esselens G; Westhovens R
Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of leflunomide in rheumatoid arthritis.
Keen HI; Conaghan PG; Tett SE
Expert Opin Drug Saf; 2013 Jul; 12(4):581-8. PubMed ID: 23668332
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide Aventis Pharma.
Kaplan MJ
Curr Opin Investig Drugs; 2001 Feb; 2(2):222-30. PubMed ID: 11816835
[TBL] [Abstract][Full Text] [Related]
15. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen.
Cutolo M; Bolosiu H; Perdriset G;
Rheumatology (Oxford); 2013 Jun; 52(6):1132-40. PubMed ID: 23401601
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group.
Rozman B
J Rheumatol Suppl; 1998 Jul; 53():27-32. PubMed ID: 9666415
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of remission with leflunomide in Wegener's granulomatosis.
Metzler C; Fink C; Lamprecht P; Gross WL; Reinhold-Keller E
Rheumatology (Oxford); 2004 Mar; 43(3):315-20. PubMed ID: 14963200
[TBL] [Abstract][Full Text] [Related]
19. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Behrens F; Koehm M; Burkhardt H
Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF.
Fiehn C; Rochel E; Ho AD; Max R
Ann Rheum Dis; 2004 Jun; 63(6):746-7. PubMed ID: 15140787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
